Synthaverse S.A. (SVE.WA)
PLN 4.28
(7.0%)
PLN 4.28
(7.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 70.04 Million PLN | 362.45% |
| 2022 | 15.14 Million PLN | 133.55% |
| 2021 | 6.48 Million PLN | -51.22% |
| 2020 | 13.29 Million PLN | 38.85% |
| 2019 | 9.57 Million PLN | -24.52% |
| 2018 | 12.68 Million PLN | -8.69% |
| 2017 | 13.89 Million PLN | -78.05% |
| 2016 | 63.3 Million PLN | 52.05% |
| 2015 | 41.63 Million PLN | 44.51% |
| 2014 | 28.8 Million PLN | 134.98% |
| 2013 | 12.25 Million PLN | 154.38% |
| 2012 | 4.81 Million PLN | -77.37% |
| 2011 | 21.29 Million PLN | -1.74% |
| 2010 | 21.67 Million PLN | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 76.01 Million PLN | 8.52% |
| 2024 Q2 | 82.63 Million PLN | 8.71% |
| 2023 Q2 | 23.88 Million PLN | 56.42% |
| 2023 Q4 | 70.04 Million PLN | 25.2% |
| 2023 FY | 70.04 Million PLN | 362.45% |
| 2023 Q3 | 55.94 Million PLN | 134.28% |
| 2023 Q1 | 15.26 Million PLN | 0.8% |
| 2022 Q3 | 9.96 Million PLN | -5.01% |
| 2022 FY | 15.14 Million PLN | 133.55% |
| 2022 Q2 | 10.49 Million PLN | 10.53% |
| 2022 Q4 | 15.14 Million PLN | 51.93% |
| 2022 Q1 | 9.49 Million PLN | 46.41% |
| 2021 Q3 | 5.69 Million PLN | 0.0% |
| 2021 Q4 | 6.48 Million PLN | 13.79% |
| 2021 FY | 6.48 Million PLN | -51.22% |
| 2021 Q1 | 15.77 Million PLN | 18.62% |
| 2020 Q2 | 14.47 Million PLN | 55.86% |
| 2020 Q4 | 13.29 Million PLN | -2.84% |
| 2020 FY | 13.29 Million PLN | 38.85% |
| 2020 Q3 | 13.68 Million PLN | -5.44% |
| 2020 Q1 | 9.28 Million PLN | -3.03% |
| 2019 Q3 | 10.07 Million PLN | -14.99% |
| 2019 Q4 | 9.57 Million PLN | -4.98% |
| 2019 Q2 | 11.85 Million PLN | -4.6% |
| 2019 Q1 | 12.42 Million PLN | -2.06% |
| 2019 FY | 9.57 Million PLN | -24.52% |
| 2018 Q3 | 12.97 Million PLN | -6.16% |
| 2018 Q1 | 13.3 Million PLN | -4.28% |
| 2018 Q4 | 12.68 Million PLN | -2.22% |
| 2018 FY | 12.68 Million PLN | -8.69% |
| 2018 Q2 | 13.82 Million PLN | 3.95% |
| 2017 Q4 | 13.89 Million PLN | -22.28% |
| 2017 FY | 13.89 Million PLN | -78.05% |
| 2017 Q2 | 20.64 Million PLN | -7.28% |
| 2017 Q3 | 17.87 Million PLN | -13.38% |
| 2017 Q1 | 22.26 Million PLN | -64.83% |
| 2016 Q4 | 63.3 Million PLN | 0.0% |
| 2016 FY | 63.3 Million PLN | 52.05% |
| 2016 Q2 | - PLN | 0.0% |
| 2016 Q3 | - PLN | 0.0% |
| 2016 Q1 | - PLN | -100.0% |
| 2015 Q4 | 41.63 Million PLN | 0.0% |
| 2015 FY | 41.63 Million PLN | 44.51% |
| 2015 Q3 | - PLN | 0.0% |
| 2015 Q2 | - PLN | 0.0% |
| 2015 Q1 | - PLN | -100.0% |
| 2014 FY | 28.8 Million PLN | 134.98% |
| 2014 Q1 | 15.13 Million PLN | 23.48% |
| 2014 Q2 | 15.38 Million PLN | 1.64% |
| 2014 Q4 | 28.8 Million PLN | 77.34% |
| 2014 Q3 | 16.24 Million PLN | 5.57% |
| 2013 Q3 | 5.43 Million PLN | 1.39% |
| 2013 Q4 | 12.25 Million PLN | 125.77% |
| 2013 Q2 | 5.35 Million PLN | 15.87% |
| 2013 Q1 | 4.62 Million PLN | -4.09% |
| 2013 FY | 12.25 Million PLN | 154.38% |
| 2012 Q4 | 4.81 Million PLN | 0.0% |
| 2012 FY | 4.81 Million PLN | -77.37% |
| 2011 FY | 21.29 Million PLN | -1.74% |
| 2010 FY | 21.67 Million PLN | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bioceltix S.A. | 175.05 Thousand PLN | -39910.968% |
| BIOTON S.A. | 68.69 Million PLN | -1.964% |
| Captor Therapeutics Spolka Akcyjna | 3.77 Million PLN | -1753.944% |
| Mabion S.A. | 35.82 Million PLN | -95.495% |
| Molecure S.A. | 7.13 Million PLN | -881.064% |
| NanoGroup S.A. | - PLN | -Infinity% |
| Pharmena S.A. | 181 Thousand PLN | -38597.238% |
| Poltreg S.A. | 8.19 Million PLN | -754.796% |
| Pure Biologics Spólka Akcyjna | 12.93 Million PLN | -441.367% |
| Ryvu Therapeutics S.A. | 906 Thousand PLN | -7630.905% |
| Urteste S.A. | 627 Thousand PLN | -11070.973% |